Could a single dose beat brain worms? new trial aims to find out
NCT ID NCT06565507
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called oxfendazole for people with mild brain cysticercosis, a parasitic infection that can cause seizures. Researchers will compare a single dose and three doses of oxfendazole against the standard combination therapy. The goal is to see if oxfendazole clears the parasites better and reduces seizure relapses. The trial plans to enroll 544 adults aged 18 to 75.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- oxfendazole
- What this could lead to
- If it works, this could provide a simpler, single-dose treatment for brain cysticercosis, reducing the need for longer drug regimens.
- What could go wrong
- This is a Phase 2/3 trial, so results are not yet known. The drug may not work better than current treatments, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN CYSTICERCOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.